United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average
Sector average (own scale)
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Chemomab Therapeutics Ltd.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | -32.18% | -38.48% | -62.02% | -161.65% | 262.35% | 73.12% |
|---|---|---|---|---|---|---|
| Sector average | 20.42% | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% |
| ROA | -25.69% | -29.58% | -41.67% | -70.89% | -242.59% | 170.53% |
| Total Assets | $35,013.00K | $25,990.98K | $17,028.28K | $8,116.27K | - | - |
| Sector average | $3,280,499.23K | $3,298,345.31K | $3,676,894.01K | |||
| Net Income | -$8,995.00K | -$9,022.02K | -$8,962.71K | -$8,912.01K | -$8,897.22K | -$9,037.06K |
| $4,262,561.28K |
| $4,994,412.92K |
| $5,761,557.24K |